Improving the anti-diabetic activity of GLP-1 by fusion with globular adiponectin

References

• Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O. 1994. Structure-activity studies of glucagon-like peptide-1. J Biol Chem. 269:6275–6278.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology. 132:2131–2157.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Huang Q, Brown TJ, Drucker DJ. 2004. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 53:2492–2500.
   PubMed Web of Science ®Google Scholar
• Burcelin R, Dolci W, Thorens B. 1999. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism. 48:252–258.
   PubMedGoogle Scholar
• Drucker DJ, Nauck MA. 2006. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368:1696–1705.
   PubMed Web of Science ®Google Scholar
• Gao M, Ma C, Liu WC, Zhu J, Tian H, Gao XD, Yao W. 2010. Production and purification of an analog of glucagon-like peptide-1 by auto-induction and on-column cleavage in Escherichia coli. World J Microbiol Biotechnol. 26:1675–1682.
   Google Scholar
• Gao M, Tian H, Ma C, Gao X, Guo W, Yao W. 2010. Expression, purification, and C-terminal site-specific PEGylation of cysteine-mutated glucagon-like peptide-1. Appl Biochem Biotechnol. 162:155–165.
   Google Scholar
• Holst JJ. 2007. The physiology of glucagon-like peptide 1. Physiol Rev. 87:1409–1439.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 116:1784–1792.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Zhou J, Martin B, Carlson OD, Maudsley S, Greig NH, Mattson MP, et al. 2010. Transferrin fusion technology: A novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Ther. 334:682–692.
   PubMed Web of Science ®Google Scholar
• Ma C, Gao M, Liu W, Zhu J, Tian H, Gao X, Yao W. 2010. Intein-mediated expression and purification of an analog of glucagon-like peptide-1 in Escherichia coli. Protein Pept Lett. 17:1245–1250.
   Google Scholar
• McEvoy RC, Andersson J, Sandler S, Hellerstrom C. 1984. Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. J Clin Invest. 74:715–722.
   PubMed Web of Science ®Google Scholar
• Nalysnyk L, Hernandez-Medina M, Krishnarajah G. 2010. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 12:288–298.
   PubMed Web of Science ®Google Scholar
• Nielsen LL. 2005. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today. 10:703–710.
   PubMed Web of Science ®Google Scholar
• Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, et al. 2003. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem. 278:9073–9085.
   PubMed Web of Science ®Google Scholar
• Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB. 2002. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 283:E745–2013;E752.
   PubMed Web of Science ®Google Scholar
• Siegel EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Folsch UR, Schrezenmeir J, et al. 1999. Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept. 79:93–102.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ III. 2011. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 13:418–425.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. 2005. PEGylation, successful approach to drug delivery. Drug Discov Today. 10:1451–1458.
   PubMed Web of Science ®Google Scholar
• Xu G, Stoffers DA, Habener JF, Bonner-Weir S. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 48:2270–2276.
   PubMed Web of Science ®Google Scholar
• Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, et al. 2010. Prevalence of diabetes among men and women in China. N Engl J Med. 362:1090–1101.
   PubMed Web of Science ®Google Scholar
• Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC. 2007. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol. 73:84–93.
   PubMed Web of Science ®Google Scholar
• ZhaoHL, YaoXQ, XueC, WangY, XiongXH, LiuZM. 2008. Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering. Protein Expr Purif. 61:73–77.
   PubMed Web of Science ®Google Scholar